^
    Back
    Association details:
    Biomarker:HER-2 exon 20 insertion + TMB-L + PD-L1 negative
    Cancer:Lung Adenocarcinoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lung Cancer
    Title:

    Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy

    Published date:
    08/03/2021
    Excerpt:
    The efficacy and outcome of chemoimmunotherapy were encouraging among ERBB2-ex20ins LUAD patients, who were characterized by low TMB and negative PD-L1 expression. The combination of TMB and comutations is a potential biomarker to identify patients who will benefit from chemoimmunotherapy.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1016/j.lungcan.2021.07.014